Our leaders

Jim Baker brings more than 15 years of experience as a biopharmaceutical communications leader building entrepreneurial, science-driven companies from discovery to commercialization, across global markets and through collaboration ecosystems. Since joining Blueprint Medicines as Vice President, Corporate Affairs in March 2017, Jim has overseen investor relations, corporate communications, global patient affairs, and internal communications. In January 2021, he was promoted to Senior Vice President, Corporate Affairs and, in January 2024, he joined the company’s executive team. During his tenure, Jim has played a key role in guiding the company’s evolution from an early development-stage enterprise to a fully integrated global biopharmaceutical company with two marketed medicines. He has helped the company raise more than $1.5 billion in capital, advanced pipeline strategy and programs as a member of the portfolio management team, and fostered and maintained a high-performance culture through periods of significant growth and change. Prior to joining us, Jim held roles of increasing responsibility in investor relations, corporate communications, new product planning and market development, and patient advocacy at Biogen, Sarepta Therapeutics, PTC Therapeutics, and Idera Pharmaceuticals. Jim received dual B.A. degrees in journalism and political science from the University of Southern California, where he was a Reserve Officer Training Corps scholar, and completed his military service as a Captain in the U.S. Army Signal Corps.

Kate brings an impressive breadth of experience and leadership within the biopharmaceutical industry, as well as a substantial background in scaling high-growth organizations, strategic business development, portfolio strategy, investor relations, and commercial execution. Since April 2022, Kate has served as President and Chief Executive Officer of Blueprint Medicines. Previously, she served as Chief Operating Officer from January 2019 to April 2022, and as Chief Business Officer from January 2016 to January 2019. Over this time, she was the founding chair of the portfolio management team, formed and executed business development strategy, drove global capital investment plans, and played a key role in capital market financings. In addition, she worked to drive the transformative growth of the company and support its evolution into a fully integrated business by developing and providing ongoing management of critical functions, including corporate development, corporate affairs, commercial strategy, international, technical operations, portfolio strategy and management, and information systems. Prior to joining Blueprint Medicines, Kate held leadership roles focused on building emerging, high-growth companies and advancing the development of innovative therapies in oncology and rare diseases as Vice President, Rare Diseases and Oncology Program Leadership at Idera Pharmaceuticals, Head of Commercial Development at Sarepta Therapeutics, Executive Director of Commercial Development at PTC Therapeutics, and roles in both corporate development and project management at Genzyme. She holds a B.A. from Wesleyan University with a double major in Molecular Biology/Biochemistry and Economics and an M.B.A. from Harvard Business School. Kate currently serves as chair of the board of directors at Fulcrum Therapeutics, as an independent director on the board of directors at Bicara Therapeutics, and as a member of the board of directors at Biotechnology Innovation Organization (BIO).

Tracey is an experienced legal professional with over 25 years of legal, management and transactional experience in the biopharmaceutical industry.  Most recently, Tracey served as senior vice president and head of legal for Sanofi Genzyme, a global business unit of Sanofi, as well as a member of Sanofi Genzyme’s executive leadership team and as a member of the leadership team for Sanofi’s global legal department.  Prior to that, Tracey served as Genzyme’s general counsel after it was acquired by Sanofi in 2011.  In her capacity as Genzyme’s general counsel, Tracey was responsible for all aspects of its legal department in the United States and throughout Europe, including general corporate, commercial and intellectual property matters, and support of business development initiatives.  Prior to Genzyme’s acquisition, Tracey was also responsible for managing the securities and employment law teams and support of non-patent litigation. Before Genzyme, Tracey was an associate at the law firm Palmer & Dodge LLP. She currently sits on the boards of directors at Kiniksa Pharmaceuticals and ImmunoGen, as well as the board of trustees at Dana Farber Cancer Institute. Tracey received her B.A. in political science from the University of Pennsylvania and her J.D. from Columbia University School of Law.

Fouad brings more than 20 years of oncology and cancer immunotherapy drug development expertise, as well as clinical experience as a pediatric oncologist. Prior to joining Blueprint Medicines, Fouad served in leadership roles at Bristol-Myers Squibb (BMS) since 1999, including as the global development lead for the company’s practice-changing cancer immunotherapy franchise. Most recently, he served as Senior Vice President and Head of Oncology Development from August 2016 to April 2020, with responsibility for driving product development plans from early-stage clinical development through commercialization across a portfolio of nearly 30 drug candidates. Previously, he served as Head of Global Medical Affairs overseeing 1,700 employees worldwide from September 2015 to September 2017, and he served as Head of Development at BMS for Opdivo® (nivolumab) and Yervoy® (ipilimumab), immunotherapy medications used in the treatment of cancer, from January 2011 to September 2015. Prior to that, he held roles of increasing responsibility within BMS. He holds an M.D. from the University of Annaba Medical School in Algeria, and a Pediatrics degree from Université Rene Descartes in Paris, France. In addition, he received a Pediatric Oncology and Hematology degree and an M.S. in clinical and experimental pharmacology from Université Paris-Sud in France.

Opdivo® and Yervoy® are registered trademarks of Bristol-Myers Squibb Company.